cbNIPT for Monogenic Disorders

About Arcedi Biotech

Arcedi Biotech, founded in 2015 and based in Copenhagen, Denmark, is a pioneer in cell-based non-invasive prenatal testing (cbNIPT). The company's proprietary platform isolates circulating fetal cells from a maternal blood draw, enabling direct, genome-wide genetic analysis of the fetus with high accuracy. This positions Arcedi to potentially disrupt the prenatal diagnostics market by offering a safer, more comprehensive alternative to invasive procedures (CVS, amniocentesis) and cell-free DNA tests. Its commercial focus is currently on its EVITA TEST product line, with a strong IP portfolio extending through 2031.

Therapeutic Areas